ClinicalTrials.gg
CompletedNCT03417154Updated May 26, 2023Results posted

Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS

A Phase 2 interventional study of Nivolumab and Low dose Cyclophosphamide (CTX) Daily in Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome, sponsored by Masonic Cancer Center, University of Minnesota. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-26.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 13 studies testing nivolumab in Leukemia, Myeloid, Acute — none open to participants now, 1 under way, none of them phase 3. Nivolumab · Leukemia, Myeloid, Acute.

Enrollment
9th of 13
12 · median 15
Started
2018
with 2 others
Phase 2
5 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Masonic Cancer Center, University of Minnesota

Among the 13 studies testing nivolumab in Leukemia, Myeloid, Acute, this one is the 9th largest by enrollment, is one of 3 that started in 2018, is one of 5 in phase 2, and was the 7th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 13 studies testing nivolumab in Leukemia, Myeloid, Acute is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Where they have run

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing nivolumab in Leukemia, Myeloid, Acute as a file.
02

Study summary

This is a phase II trial of nivolumab and low dose cyclophosphamide (CTX) when given in combination to patients with relapsed/refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (MDS) who are not eligible for or decline hematopoietic stem cell transplant. It includes a randomized pilot sub-study during stage 1.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Higher Risk Myelodysplastic Syndrome

Keywords

  • AML
  • MDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Meets one of the following disease criteria:

    • Primary (de novo) AML or higher-risk MDS with induction failure: No CR after 2 or more induction attempts with high dose chemotherapy or hypomethylating agents or other agents; no CR after 1 induction attempt and not eligible for a 2nd induction.. Higher risk MDS defined as risk score > 4.5 based on the revised IPSS criteria.
    • Secondary AML (from antecedent hematologic or treatment-related): Not in CR after 1 or more cycles of chemotherapy.
    • AML: Blasts ≥5% in bone marrow or peripheral blood after prior attainment of CR; relapse at any time but currently ≥100 days following HCT.
    • Relapsed MDS: Morphologic evidence of relapse or increase in blasts ≥5% in bone marrow or peripheral blood after prior attainment of hematologic improvement; or partial or complete response ; relapse at any time but currently ≥100 days following allogeneic HCT..
  • Performance Status ≤ 2 - refer to Appendix II
  • Adequate organ function within 14 days of study registration defined as:

    • Absolute Lymphocyte Count: ≥ 500 cells/mm3
    • Hepatic: total ≤ 3 x upper limit of institutional normal (); and AST ≤ 5 x ULN
    • Renal: Serum creatinine ≤ 2 mg/dL
    • Pulmonary: No oxygen requirement on room air or requiring ≤ 2L supplemental O2
  • Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective during therapy and continuing (23 weeks for females, 31 weeks for males) after the last dose of nivolumab
  • Voluntary written consent

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding -The agents used in this study fall under Pregnancy Category D - Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. Women of must have a negative pregnancy test (urine or serum) within 7 days of study drug administration.
  • Prior hematopoietic stem cell transplantation within previous 100 days (note patients with a prior alloHSCT receive nivolumab at the reduced dose of 1 mg/kg)
  • Signs or symptoms of active
  • Active pneumonitis or uncontrolled infection
  • Received chemotherapy drugs within previous 2 weeks
  • Estimated \<28 days in the opinion of the enrolling investigator
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Arm 1: Nivolumab every 2 weeks and Cyclophosphamide daily

    Drug: Nivolumab · Drug: Low dose Cyclophosphamide (CTX) Daily

  • Experimental
    Arm 2: Nivolumab every 2 weeks and Cyclophosphamide every 7 days

    Drug: Nivolumab · Drug: Low dose Cyclophosphamide (CTX) Every 7 Days

Interventions

  • 3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.

    Also known as: Opdivo

  • DrugLow dose Cyclophosphamide (CTX) Daily

    Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment

    Also known as: CTX

  • DrugLow dose Cyclophosphamide (CTX) Every 7 Days

    Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment

    Also known as: CTX

06

What researchers measure

Primary outcomes

  1. Stage 1: Dosing Schedule of Low-dose Cyclophosphamide

    Number of participants with adverse events

    Time frame: 4 weeks from start of treatment

  2. Clinical Benefit and Immunologic Response of the Combination Therapy

    Overall response rate at 90 days from treatment start. Response is defined as CR + CRi + CRp + PR in AML and CR/PR/hematologic improvement (HI) in MDS. Complete Remission (CR) - subjects must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state, an ANC \> 1 x 109/L and platelet count ≥ 100 x 109/L and normal marrow differential with \< 5% blasts, and they will be RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia Complete Remission with Incomplete Hematologic Recovery (CRi) - subjects must fulfill all the criteria for CR except for incomplete hematological recovery Complete Remission with Incomplete Platelet Recovery (CRp) - subjects must achieve CR except for incomplete platelet recovery Partial Remission (PR) - subjects must have ≥50% bone marrow blast reduction or decrease to 5 to 25%

    Time frame: 90 days from start of treatment

Secondary outcomes

  1. Objective Response Rate (ORR)

    Incidence of overall response.

    Time frame: 30 days from start of treatment

  2. Progression Free Survival (PFS)

    Incidence of progression free survival.

    Time frame: 6 months from start of treatment

  3. Overall Survival (OS)

    Incidence of overall survival.

    Time frame: 6 months from start of treatment

07

Results

Posted May 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Started66
Completed00
Not completed66

Outcome measures

PrimaryStage 1: Dosing Schedule of Low-dose Cyclophosphamide

Number of participants with adverse events

Time frame:
4 weeks from start of treatment
Reported as:
Count of participants · Participants
Stage 1: Dosing Schedule of Low-dose Cyclophosphamide
ParticipantsArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Stage 1: Dosing Schedule of Low-dose Cyclophosphamide66
PrimaryClinical Benefit and Immunologic Response of the Combination Therapy

Overall response rate at 90 days from treatment start. Response is defined as CR + CRi + CRp + PR in AML and CR/PR/hematologic improvement (HI) in MDS. Complete Remission (CR) - subjects must have bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state, an ANC \> 1 x 109/L and platelet count ≥ 100 x 109/L and normal marrow differential with \< 5% blasts, and they will be RBC and platelet transfusion independent (defined as 1 week without RBC transfusion and 1 week without platelet transfusion). There should be no evidence of extramedullary leukemia Complete Remission with Incomplete Hematologic Recovery (CRi) - subjects must fulfill all the criteria for CR except for incomplete hematological recovery Complete Remission with Incomplete Platelet Recovery (CRp) - subjects must achieve CR except for incomplete platelet recovery Partial Remission (PR) - subjects must have ≥50% bone marrow blast reduction or decrease to 5 to 25%

Time frame:
90 days from start of treatment
Reported as:
Count of participants · Participants
Clinical Benefit and Immunologic Response of the Combination Therapy
ParticipantsArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Clinical Benefit and Immunologic Response of the Combination Therapy00
SecondaryObjective Response Rate (ORR)

Incidence of overall response.

Time frame:
30 days from start of treatment
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Objective Response Rate (ORR)00
SecondaryProgression Free Survival (PFS)

Incidence of progression free survival.

Time frame:
6 months from start of treatment
Reported as:
Count of participants · Participants
Progression Free Survival (PFS)
ParticipantsArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Progression Free Survival (PFS)00
SecondaryOverall Survival (OS)

Incidence of overall survival.

Time frame:
6 months from start of treatment
Reported as:
Count of participants · Participants
Overall Survival (OS)
ParticipantsArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Overall Survival (OS)45

Adverse events

Collected over Adverse events were collected from on treatment date up until 6 months after the off treatment date, on average of 1 year.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide Daily2/6 (33.3%)3/6 (50%)4/6 (66.7%)
Arm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days1/6 (16.7%)5/6 (83.3%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specifyNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/62/6
Febrile neutropeniaBlood and lymphatic system disorders1/62/6
Lung infectionInfections and infestations1/61/6
Most frequent other events
Most frequent other events
EventArm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 Days
GI DisordersGastrointestinal disorders3/66/6
Edema limbsGeneral disorders2/63/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 DaysTotal
<=18 years000
Between 18 and 65 years325
>=65 years347
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 DaysTotal
Female549
Male123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 DaysTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White5611
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Arm 1: Nivolumab Every 2 Weeks and Cyclophosphamide DailyArm 2: Nivolumab Every 2 Weeks and Cyclophosphamide Every 7 DaysTotal
United States6612
08

Study locations

1 site
  • University of Minnesota Masonic Cancer Center
    Minneapolis, Minnesota 55455, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Jan 2022, 41 months.

Results were first posted in May 2023, 1 year 4 months after primary completion.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's 41 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2018
First posted
Jan 31, 2018
StartActual
Aug 13, 2018
Primary completionActual
Jan 25, 2022
CompletionActual
Jan 25, 2022
Results first posted
May 26, 2023
Last update
May 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03417154
Responsible party
Sponsor
First posted
Jan 31, 2018
Start date
Aug 13, 2018
Primary completion
Jan 25, 2022
Completion
Jan 25, 2022
Results posted
May 26, 2023
Last update
May 26, 2023

Study contacts

Fiona He, MD
principal investigator · Division of Hematology, Oncology and Transplantation, Masonic Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion